JP2005512521A5 - - Google Patents

Download PDF

Info

Publication number
JP2005512521A5
JP2005512521A5 JP2003536444A JP2003536444A JP2005512521A5 JP 2005512521 A5 JP2005512521 A5 JP 2005512521A5 JP 2003536444 A JP2003536444 A JP 2003536444A JP 2003536444 A JP2003536444 A JP 2003536444A JP 2005512521 A5 JP2005512521 A5 JP 2005512521A5
Authority
JP
Japan
Prior art keywords
tnf
protein
alpha
mutant
substitution
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2003536444A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005512521A (ja
JP4353802B2 (ja
Filing date
Publication date
Priority claimed from US09/981,289 external-priority patent/US7101974B2/en
Application filed filed Critical
Publication of JP2005512521A publication Critical patent/JP2005512521A/ja
Publication of JP2005512521A5 publication Critical patent/JP2005512521A5/ja
Application granted granted Critical
Publication of JP4353802B2 publication Critical patent/JP4353802B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2003536444A 2001-10-15 2002-09-30 Tnf−アルファ関連障害を処置するための、タンパク質をベースとするtnf−アルファ変異体 Expired - Lifetime JP4353802B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/981,289 US7101974B2 (en) 2000-03-02 2001-10-15 TNF-αvariants
PCT/US2002/031277 WO2003033720A2 (en) 2001-10-15 2002-09-30 Protein based tnf-alpha variants for the treatment of tnf-alpha related disorders

Publications (3)

Publication Number Publication Date
JP2005512521A JP2005512521A (ja) 2005-05-12
JP2005512521A5 true JP2005512521A5 (https=) 2006-01-05
JP4353802B2 JP4353802B2 (ja) 2009-10-28

Family

ID=25528271

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003536444A Expired - Lifetime JP4353802B2 (ja) 2001-10-15 2002-09-30 Tnf−アルファ関連障害を処置するための、タンパク質をベースとするtnf−アルファ変異体

Country Status (5)

Country Link
US (1) US7101974B2 (https=)
EP (1) EP1578988B1 (https=)
JP (1) JP4353802B2 (https=)
CA (1) CA2461245A1 (https=)
WO (1) WO2003033720A2 (https=)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7244823B2 (en) * 2000-03-02 2007-07-17 Xencor TNF-alpha variants proteins for the treatment of TNF-alpha related disorders
US20070172449A1 (en) * 2000-03-02 2007-07-26 Xencor, Inc. TNF-alpha VARIANT FORMULATIONS FOR THE TREATMENT OF TNF-alpha RELATED DISORDERS
US7687461B2 (en) * 2000-03-02 2010-03-30 Xencor, Inc. Treatment of TNF-α related disorders with TNF-α variant proteins
US7381792B2 (en) * 2002-01-04 2008-06-03 Xencor, Inc. Variants of RANKL protein
US20030166559A1 (en) * 2002-01-04 2003-09-04 Desjarlais John R. Dominant negative proteins and methods thereof
US7662925B2 (en) 2002-03-01 2010-02-16 Xencor, Inc. Optimized Fc variants and methods for their generation
US20090042291A1 (en) * 2002-03-01 2009-02-12 Xencor, Inc. Optimized Fc variants
US20070010658A1 (en) * 2002-10-29 2007-01-11 Holtet Thor L Trimeric binding proteins for trimeric cytokines
US7553930B2 (en) * 2003-01-06 2009-06-30 Xencor, Inc. BAFF variants and methods thereof
US20060014248A1 (en) * 2003-01-06 2006-01-19 Xencor, Inc. TNF super family members with altered immunogenicity
US20050221443A1 (en) * 2003-01-06 2005-10-06 Xencor, Inc. Tumor necrosis factor super family agonists
US20050130892A1 (en) * 2003-03-07 2005-06-16 Xencor, Inc. BAFF variants and methods thereof
US20090010920A1 (en) * 2003-03-03 2009-01-08 Xencor, Inc. Fc Variants Having Decreased Affinity for FcyRIIb
US8388955B2 (en) * 2003-03-03 2013-03-05 Xencor, Inc. Fc variants
US7587286B2 (en) * 2003-03-31 2009-09-08 Xencor, Inc. Methods for rational pegylation of proteins
US7610156B2 (en) * 2003-03-31 2009-10-27 Xencor, Inc. Methods for rational pegylation of proteins
US7642340B2 (en) 2003-03-31 2010-01-05 Xencor, Inc. PEGylated TNF-α variant proteins
US9714282B2 (en) 2003-09-26 2017-07-25 Xencor, Inc. Optimized Fc variants and methods for their generation
US8101720B2 (en) 2004-10-21 2012-01-24 Xencor, Inc. Immunoglobulin insertions, deletions and substitutions
EP1675871A2 (en) * 2003-10-10 2006-07-05 Xencor Inc. Protein based tnf-alpha variants for the treatment of tnf-alpha related disorders
TW200526780A (en) * 2004-01-06 2005-08-16 Hayashibara Biochem Lab TNF antagonists and TNF inhibitors comprising the same as the active ingredient
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
AU2005304624B2 (en) 2004-11-12 2010-10-07 Xencor, Inc. Fc variants with altered binding to FcRn
US8802820B2 (en) 2004-11-12 2014-08-12 Xencor, Inc. Fc variants with altered binding to FcRn
US8546543B2 (en) 2004-11-12 2013-10-01 Xencor, Inc. Fc variants that extend antibody half-life
WO2007041635A2 (en) 2005-10-03 2007-04-12 Xencor, Inc. Fc variants with optimized fc receptor binding properties
CA2672229A1 (en) * 2006-12-14 2008-06-19 Actogenix N.V. Delivery of binding molecules to induce immunomodulation
HRP20150279T1 (hr) 2007-12-26 2015-05-08 Xencor, Inc. Fc inaäśice s promijenjenim vezanjem na fcrn
US12492253B1 (en) 2008-02-25 2025-12-09 Xencor, Inc. Anti-human C5 antibodies
PE20120835A1 (es) 2009-04-16 2012-07-23 Abbvie Biotherapeutics Inc Anticuerpos anti-tnf-alfa y sus usos
WO2011028952A1 (en) 2009-09-02 2011-03-10 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
US9445990B2 (en) 2010-10-06 2016-09-20 Medtronic, Inc. TNF inhibitor formulation for use in implantable infusion devices
US9060978B2 (en) 2011-01-24 2015-06-23 Warsaw Orthopedic, Inc. Method for treating an intervertebral disc disorder by administering a dominant negative tumor necrosis factor antagonist
US9534056B2 (en) * 2011-06-06 2017-01-03 Immungene Inc Engineered TAA antibody-TNFSF member ligand fusion molecules
JP2017525370A (ja) 2014-08-21 2017-09-07 ザ ジェネラル ホスピタル コーポレイション 腫瘍壊死因子スーパーファミリーおよびtnf様リガンドムテインならびに腫瘍壊死因子スーパーファミリーおよびtnf様リガンドムテインを調製および使用する方法
WO2016179430A1 (en) 2015-05-05 2016-11-10 Rubicon Biotechnology Llc Cancer immunotherapeutic
GB201510758D0 (en) 2015-06-18 2015-08-05 Ucb Biopharma Sprl Novel TNFa structure for use in therapy
CA2993760A1 (en) * 2015-07-28 2017-02-02 Yeda Research And Development Co. Ltd. Stable proteins and methods for designing same
WO2017077382A1 (en) * 2015-11-06 2017-05-11 Orionis Biosciences Nv Bi-functional chimeric proteins and uses thereof
CN106800597B (zh) * 2015-11-26 2021-07-16 上海佳文英莉生物技术有限公司 一种中和促细胞程序性坏死抗体的蛋白及其应用
CN116769054A (zh) 2016-02-05 2023-09-19 奥里尼斯生物科学私人有限公司 双特异性信号传导剂及其用途
US11661455B2 (en) 2016-02-05 2023-05-30 Orionis Biosciences BV Chimeric protein comprising an interferon alpha 2mutant and a PD-L1 binding moiety
EP3426278B1 (en) 2016-03-07 2024-01-03 Vib Vzw Cd20 binding single domain antibodies
EP3455245A2 (en) 2016-05-13 2019-03-20 Orionis Biosciences NV Therapeutic targeting of non-cellular structures
WO2017194783A1 (en) 2016-05-13 2017-11-16 Orionis Biosciences Nv Targeted mutant interferon-beta and uses thereof
WO2018077893A1 (en) 2016-10-24 2018-05-03 Orionis Biosciences Nv Targeted mutant interferon-gamma and uses thereof
JP6925431B2 (ja) 2016-11-09 2021-08-25 フィロジェン エッセ.ピー.アー. Il2及びtnf突然変異体のイムノコンジュゲート
GB201621907D0 (en) 2016-12-21 2017-02-01 Ucb Biopharma Sprl And Sanofi Antibody epitope
KR102642385B1 (ko) 2017-02-06 2024-03-04 오리오니스 바이오사이언시스 엔브이 표적화된 키메라 단백질 및 이의 용도
CN110573172A (zh) 2017-02-06 2019-12-13 奥里尼斯生物科学有限公司 靶向的工程化干扰素及其用途
WO2018146074A1 (en) 2017-02-07 2018-08-16 Vib Vzw Immune-cell targeted bispecific chimeric proteins and uses thereof
EP3664829A4 (en) 2017-08-09 2021-05-05 Orionis Biosciences, Inc. LIAISON OFFICERS AT PD-1 AND PD-L1
AU2018313810B2 (en) 2017-08-09 2025-05-15 Orionis Biosciences BV Clec9A binding agents and use thereof
CN111511763B (zh) 2017-08-09 2024-05-31 奥里尼斯生物科学有限公司 Cd8结合剂
WO2020033646A1 (en) 2018-08-08 2020-02-13 Orionis Biosciences, Inc. SIRP1α TARGETED CHIMERIC PROTEINS AND USES THEREOF
US12410225B2 (en) 2018-11-08 2025-09-09 Orionis Biosciences, Inc Modulation of dendritic cell lineages
US12351614B2 (en) 2019-03-28 2025-07-08 Orionis Biosciences, Inc. CLEC9A-based chimeric protein complexes
US11440943B2 (en) 2019-03-28 2022-09-13 Orionis Biosciences, Inc. Therapeutic interferon alpha 1 proteins
CN111909267B (zh) * 2019-05-07 2022-03-25 北京天成新脉生物技术有限公司 低免疫原性抗TNF-α人源化单克隆抗体TCX063及其应用
WO2020257412A1 (en) 2019-06-19 2020-12-24 Orionis Biosciences, Inc. Combination therapy with cd13-targeted chimeric proteins or chimeric protein complexes
US12564620B2 (en) 2021-09-15 2026-03-03 Virginia Commonwealth University Treatment of gulf war illness

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US5288852A (en) 1984-03-06 1994-02-22 Dainippon Pharmaceutical Co., Ltd. Human tumor necrosis factor polypeptides
US4879226A (en) 1984-04-06 1989-11-07 Asahi Kasei Kogyo Kabushiki Kaisha Novel human physiologically active polypeptide
US4677063A (en) 1985-05-02 1987-06-30 Cetus Corporation Human tumor necrosis factor
US4677064A (en) 1984-11-09 1987-06-30 Cetus Corporation Human tumor necrosis factor
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
US4894439A (en) 1986-05-22 1990-01-16 Cetus Corporation N-terminal derivatives of tumor necrosis factor purified by microporous PTFE membranes
EP0247906B1 (en) 1986-02-04 1994-12-28 Mizuno, Den'Ichi DNA coding for anti-tumour polypeptides, the polypeptides and anti-tumour agents comprising said polypeptides
WO1987005330A1 (en) 1986-03-07 1987-09-11 Michel Louis Eugene Bergh Method for enhancing glycoprotein stability
DE3750056T2 (de) 1986-06-20 1995-04-06 Dainippon Pharmaceutical Co Polypeptid-Mutanten des menschlichen TNF und für diese Mutanten codierende DNS.
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
JPS6330426A (ja) 1986-07-25 1988-02-09 Mitsubishi Chem Ind Ltd 自己免疫性疾患治療薬
JPH07106158B2 (ja) 1986-12-04 1995-11-15 サントリー株式会社 抗腫瘍活性を有する新規ポリペプチドおよびその製造法
US5151349A (en) 1986-12-04 1992-09-29 Suntory Limited Method for expressing polypeptide having anti-tumor activity
DE3716513A1 (de) 1987-05-16 1988-11-24 Basf Ag Proteine mit tnf-wirkung
IL83878A (en) * 1987-09-13 1995-07-31 Yeda Res & Dev Soluble protein corresponding to tnf inhibitory protein its preparation and pharmaceutical compositions containing it
US5512544A (en) 1987-09-13 1996-04-30 Yeda Research And Development Co. Ltd. Pharmaceutical compositions comprising an anticytokine
JPH0797997B2 (ja) 1988-04-28 1995-10-25 帝人株式会社 新規生理活性ポリペプチド
US5262309A (en) 1988-09-22 1993-11-16 Teijin Limited Terminal modifications of tumor necrosis factor
DE3841768A1 (de) 1988-12-12 1990-06-13 Basf Ag Neue tnf-peptide
DE3843534A1 (de) 1988-12-23 1990-07-12 Basf Ag Neue tnf-polypeptide
JP3203599B2 (ja) 1989-10-24 2001-08-27 カイロン コーポレイション 感染性タンパク質デリバリーシステム
JP2685608B2 (ja) 1989-12-08 1997-12-03 帝人株式会社 新規生理活性ポリペプチド
JPH03297388A (ja) 1990-04-17 1991-12-27 Ube Ind Ltd 新規なtnf変異体、その製造法及びそれを有効成分とする抗腫瘍剤
JPH0479880A (ja) 1990-07-24 1992-03-13 Ishihara Sangyo Kaisha Ltd ポリペプチド
JPH04368398A (ja) 1991-06-17 1992-12-21 Ishihara Sangyo Kaisha Ltd ポリペプチド
JPH05255393A (ja) 1990-09-21 1993-10-05 Ishihara Sangyo Kaisha Ltd ポリペプチド
JP3157571B2 (ja) 1990-09-21 2001-04-16 石原産業株式会社 ポリペプチド
JPH04182498A (ja) 1990-11-16 1992-06-30 Ishihara Sangyo Kaisha Ltd ポリペプチド
JPH04182497A (ja) 1990-11-16 1992-06-30 Ishihara Sangyo Kaisha Ltd ポリペプチド
CA2055168A1 (en) 1990-11-21 1992-05-22 Walter Fiers Tnf-muteins
US5160483A (en) 1991-05-07 1992-11-03 The University Of Tennessee Research Corporation Fragment of TNF-α for promoting wound healing
IL99120A0 (en) 1991-08-07 1992-07-15 Yeda Res & Dev Multimers of the soluble forms of tnf receptors,their preparation and pharmaceutical compositions containing them
JPH05271289A (ja) 1992-03-17 1993-10-19 Ishihara Sangyo Kaisha Ltd ポリペプチド
US5891679A (en) 1993-02-03 1999-04-06 N.V. Innogenetics S.A. TNF-alpha muteins and a process for preparing them
KR970005042B1 (ko) * 1993-02-09 1997-04-11 한일합성섬유공업 주식회사 종양괴사인자-알파 뮤테인
CA2119089A1 (en) 1993-03-29 1994-09-30 David Banner Tumor necrosis factor muteins
US5606023A (en) 1994-05-24 1997-02-25 Thomas Jefferson University Mutant tumor necrosis factor proteins
US5888814A (en) 1994-06-06 1999-03-30 Chiron Corporation Recombinant host cells encoding TNF proteins
DK0974111T3 (da) 1997-04-11 2003-04-22 California Inst Of Techn Apparat og metode til automatiseret design af proteiner
EP0980258A1 (en) 1997-05-12 2000-02-23 The Kennedy Institute Of Rheumatology Suppression of tumor necrosis factor alpha and vascular endothelial growth factor in therapy
AU774334B2 (en) 1998-10-16 2004-06-24 Xencor Protein design automation for protein libraries
WO2001025277A1 (en) 1999-10-07 2001-04-12 Maxygen Aps Single-chain antagonist polypeptides
JP2003525612A (ja) * 2000-03-02 2003-09-02 ゼンコー TNF−α関連障害の処置のための変種TNF−αタンパク質の設計および発見
US7056695B2 (en) * 2000-03-02 2006-06-06 Xencor TNF-α variants

Similar Documents

Publication Publication Date Title
JP2005512521A5 (https=)
JP4516719B2 (ja) Tall−1と結合するペプチド及び関連分子
TWI250988B (en) Thrombopoietic compounds
Zdanov Structural features of the interleukin-10 family of cytokines
JP6474786B2 (ja) 虚血性損傷の治療及び予防用の組成物
JP2018515085A5 (https=)
WO2008000516B1 (en) IMPROVED sgp130Fc DIMERS
MX2012002428A (es) Compuestos de union il-17 y usos medicos de los mismos.
CN103172746A (zh) 三聚体Fc融合蛋白及其用途
JP2002514418A5 (https=)
JP2020528743A5 (https=)
Lambris et al. Third component of trout complement. cDNA cloning and conservation of functional sites.
JP2023553697A5 (https=)
KR20140135766A (ko) 종양괴사인자 수용체 융합 단백질 및 이를 이용하는 방법
IL106271A (en) Ligand to TNF 75P receptor and its preparation
CA2407086A1 (en) Integrin/adhesion antagonists
US7820622B2 (en) TNF antagonists
MX2011005363A (es) Peptidos para inhibicion del factor alfa de necrosis tumoral y usos de los mismos.
CA2404429A1 (en) Malaria plasmodium antigen polypeptide se36, method of purifying the same and vaccine and diagnostic with the use of the thus obtained antigen
AU2020270242B2 (en) Anti-TNF-α humanized monoclonal antibody TCX060 having low immunogenicity and low ADCC/CDC function, and use thereof
JP2024546916A5 (https=)
JPH05262788A (ja) ペプチド類、その設計方法及び製造方法並びに受容体上の生理活性ペプチドの結合部位の決定方法
KR20250138100A (ko) 응집체 성장 억제 기능을 갖는 생물학적 고분자 합성용 기재 및 이를 이용한 생물학적 고분자 합성
JPH01139597A (ja) ペプチド
RU2025139088A (ru) Сконструированные варианты il-7 и способы их использования